Premium
Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome
Author(s) -
Sakamoto Minami,
Miyagaki Tomomitsu,
Kamijo Hiroaki,
Oka Tomonori,
Takahashi Naomi,
Suga Hiraku,
Yoshizaki Ayumi,
Asano Yoshihide,
Sugaya Makoto,
Sato Shinichi
Publication year - 2018
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.14033
Subject(s) - mycosis fungoides , angiogenesis , vascular endothelial growth factor , thymic stromal lymphopoietin , vegf receptors , medicine , cancer research , stromal cell , immunology , pathology , lymphoma , cytokine
Angiogenesis is an important step to support progression of malignancies, including mycosis fungoides ( MF ) and Sézary syndrome ( SS ). Vascular endothelial growth factor ( VEGF )‐A, a key player in angiogenesis, is secreted by tumor cells of MF / SS and its expression levels in lesional skin correlated with disease severity. In this study, we examined serum VEGF ‐A levels in MF / SS patients. Serum VEGF ‐A levels were elevated in patients with erythrodermic MF / SS and the levels decreased after treatment. Importantly, serum VEGF ‐A levels positively correlated with markers for pruritus. We also found that VEGF ‐A upregulated mRNA expression of thymic stromal lymphopoietin by keratinocytes. Taken together, our study suggests that VEGF ‐A can promote progression and pruritus in MF / SS . Inhibition of VEGF ‐A signaling can be a therapeutic strategy for patients with erythrodermic MF / SS .